Latest Cancer Research Stories
LOS ANGELES, April 25, 2013 /PRNewswire/ -- Stand Up To Cancer (SU2C) is proud to unveil the second public service announcement (PSA) to feature Ambassador Heidi Klum, which will make its debut in PEOPLE magazine's World's Most Beautiful issue on newsstands now. In the print PSA photographed by Rankin, Klum lends her signature style to the fight against cancer, posing in a white SU2C tank top and black leather pants. The PSA will also be featured over a number of billboards in Times...
Sweeping study of cancer metabolism identifies hundreds of alterations and potential drug targets to starve tumors A massive study analyzing gene expression data from 22 tumor types has identified multiple metabolic expression changes associated with cancer. The analysis, conducted by researchers at Columbia University Medical Center, also identified hundreds of potential drug targets that could cut off a tumor's fuel supply or interfere with its ability to synthesize essential building...
polyDNA recommends Gene-Eden-VIR for people concerned about the relationship between asymptomatic HPV infection and lung cancer. Rochester, NY (PRWEB) April 21, 2013 Almost everyone knows that HPV can cause genital warts and even cervical cancer. As it turns out, new research shows that the same strains of HPV that can cause cervical cancer may also trigger lung cancer. (1) It is important to note that while cervical cancer has warning signs such as cervical displasia, lung cancer often...
A new, pre-clinical study by researchers at Virginia Commonwealth University Massey Cancer Center suggests that a novel drug combination could lead to profound leukemia cell death by disrupting the function of two major pro-survival proteins. The effectiveness of the therapy lies in its ability to target a pro-survival cell signaling pathway known as PI3K/AKT/mTOR, upon which the leukemia cells have become dependent. In the study, published in the journal Cancer Research, researchers...
Researchers at The Jackson Laboratory have identified a molecule that prevents repair of some cancer cells, providing a potential new "genetic chemotherapy" approach to cancer treatment that could significantly reduce side effects and the development of treatment resistance compared with traditional chemotherapy. In healthy people, white blood cells called B cells (or B lymphocytes) are a kind of sophisticated tool kit, making antibodies against pathogens or other invaders. In the process...
WESTMINSTER, Md., April 16, 2013 /PRNewswire-USNewswire/ -- The Joanna M. Nicolay Melanoma Foundation (JMNMF) awarded ten $10,000, nationally competitive, "Research Scholar Awards" (RSA) to exceptional graduate student melanoma researchers at leading cancer centers across the U.S. The JMNMF increased funding again in 2013, to significantly enhance the potential for advancements in the melanoma cancer field; and, to increase the number of young scientists choosing melanoma research as...
DUBLIN, April 15, 2013 /PRNewswire/ -- Research and Markets has announced the addition of the "Isothermal Nucleic Acid Amplification Technologies Market 2012-2017: Molecular Diagnostics, Infectious Disease Testing, Blood Screening, Cancer Research, Rapid Testing [http://www.researchandmarkets.com/research/2fxss7/isothermal ]" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Isothermal Nucleic Acid Amplification Technologies...
Certain types of papilloma virus might actually prevent cervical cancer, according to a new study by researchers from The University of Manchester. There are over 100 different types of human papilloma virus (HPV). Cervical cancer is known to be caused by infection with approximately 14 so-called “high-risk” types of this virus. Researchers from Manchester looked at the different types of HPV found in cervical smears and invasive cervical cancers from HIV positive and HIV negative...
New Pre-Clinical Data Presented at AACR Annual Meeting in Washington, DC SAN DIEGO, April 10, 2013 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced the presentation of new data showing the ability of its mitochondrial inhibitor drug candidate, ME-344, to decrease tumor burden and delay recurrence in a pre-clinical in vivo model of recurrent epithelial ovarian cancer, the most lethal of...
Study of RNA interference drug presented at AACR Annual Meeting 2013 The safety and preliminary efficacy of a new class of tumor fighting drugs were reported today by Scottsdale Healthcare's Virginia G. Piper Cancer Center Clinical Trials and the Translational Genomics Research Institute (TGen). Early results from the phase I, first in-human study of an RNA interference (RNAi) drug were announced during the American Association for Cancer Research (AACR) Annual Meeting 2013, April 6-10,...
